Artelo Biosciences to Present at the 2021 Ladenburg Thalmann Healthcare Conference on July 14th
Artelo Biosciences (NASDAQ: ARTL), a clinical-stage biopharmaceutical company, will present at the 2021 Ladenburg Thalmann Healthcare Conference on July 14, 2021, at 3:00 p.m. EST. During the virtual event, CEO Gregory D. Gorgas will discuss the company’s focus on therapeutics targeting lipid signaling pathways, particularly the endocannabinoid system. Artelo aims to address significant unmet medical needs across various conditions, including cancer and PTSD. Interested parties can access the presentation via a live webcast.
- None.
- None.
LA JOLLA, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced that management will be presenting and hosting 1x1 meetings during the Ladenburg Thalmann Healthcare Conference taking place virtually July 13-14, 2021.
Gregory D. Gorgas, Artelo’s President and Chief Executive Officer, is scheduled to host a virtual presentation during the event as follows:
2021 Ladenburg Thalmann Healthcare Conference
Date: Wednesday, July 14, 2021
Time: 3:00 p.m. EST / 12:00 p.m. PST
Webcast: https://wsw.com/webcast/ladenburg7/artl/2425233
About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that target lipid signaling pathways, including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the San Diego-based company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.
Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: ARTL@crescendo-ir.com
FAQ
When will Artelo Biosciences present at the Ladenburg Thalmann Healthcare Conference?
Who will represent Artelo Biosciences at the conference?
How can I watch the Artelo Biosciences presentation?
What is the focus of Artelo Biosciences' therapeutics?
What conditions does Artelo Biosciences aim to address?
